Recursion Pharmaceuticals: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Recursion Pharmaceuticals (NASDAQ:RXRX) reported Q3 earnings, missing estimated earnings by 13.16% with an EPS of $-0.43 versus an estimate of $-0.38. Revenue was down $2.63 million from the same period last year. Last quarter, the company also missed on EPS by $0.01, which was followed by a 5.02% drop in the share price the next day.

November 09, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Recursion Pharmaceuticals missed Q3 earnings estimates and saw a decrease in revenue YoY. A similar miss last quarter led to a drop in share price.
Recursion Pharmaceuticals missed its Q3 earnings estimates by 13.16% and reported a decrease in revenue compared to the same period last year. This is likely to negatively impact the company's stock price in the short term, especially considering that a similar miss in the previous quarter led to a 5.02% drop in the share price the next day.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100